$3.05+3.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Just reported
From Protalix Biotherapeutics, Inc.'s results release of November 10, 2026; its quarterly report has since been filed.
Actual
$21.9M
+23% y/y
+10% q/q
Guided
—
No guide given
Actual
$0.05
+67% y/y
0.0% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $21.9M | $17.9M | +22.82% |
| Profit | $4M | $2.4M | +68.20% |
| Profit per share | $0.05 | $0.03 | +66.67% |
| Free Cash Flow | $3.2M | -$4.2M | +174.87% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Protalix Biotherapeutics, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Gout Gout is a metabolic disorder characterized by elevated blood uric acid that causes recurrent inflammatory arthritis and joint damage. An estimated 11.3 million people in the U.S. have gout. 1 Rheumatologists report that approximately 25% of their patients have blood uric acid levels above target, which can lead to uncontrolled gout. 2 An estimated 180,000 patients in the U.S. have uncontrolled gout. 2 Uncontrolled gout is a severe disease with high morbidity, severe pain, and low quality of life.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Protalix Biotherapeutics, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$4M
+90% y/y
-13% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.